Search

everythinglearnresearchcommunity

for

Search:↓

Docetaxel and oxaliplatin are effective and have manageable side effects for recurrent platinum-sensitive ovarian cancer.

The drug TGU was ineffective against small cell lung cancer and caused significant bone marrow suppression.

Etanercept is safe and may help improve hidradenitis suppurativa, but more research is needed.

The treatment combining docetaxel, cisplatin, and 5-FU is feasible and effective for advanced head and neck cancer.

KX-826 is safe and effectively increases hair count in men with hair loss.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

The drug combination was safe and showed promise in treating advanced tumors.

Tempol is safe and may prevent hair loss from brain radiotherapy.

Bexarotene 1% topical gel helped some patients with alopecia areata regrow hair.

The new chemotherapy combination for advanced lung cancer showed a 35.7% response rate but caused significant side effects.

Boron neutron capture therapy for head and neck cancer can cause side effects like mouth sores and skin irritation, which vary depending on where the treatment is aimed.

Giving docetaxel weekly at 40 mg/m² is manageable and has low toxicity for cancer patients.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Patients with metastatic breast cancer treated with epirubicin and docetaxel had a good response and maintained their quality of life.

Wearing a frozen glove during chemotherapy can reduce nail and skin problems but may not be comfortable for everyone.

The combination treatment showed a higher response rate but no significant survival benefits.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

BAY 43-9006 helps control kidney cancer growth but doesn't significantly increase overall survival.

Liposomes show promise in cancer treatment by delivering drugs with less toxicity and improved effectiveness.

In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations.

PLD is an effective and safer alternative for treating breast cancer.

JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Dutasteride 0.5 mg daily improves hair growth safely in men with hair loss.

Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.

Bendamustine, often combined with other drugs, is effective and less toxic for certain blood cancers, but less effective for young, fit patients with CLL.

Docetaxel is safe and works well for older people with cancer, with manageable side effects.

Epirubicin is as effective as doxorubicin for cancer treatment with less heart damage, but doesn't work on doxorubicin-resistant cancers.

Capecitabine is as effective as intravenous treatments with fewer side effects, but requires careful management of Hand-foot syndrome and patient education.

Multimodal primary treatment improves survival in premenopausal breast cancer patients and is also beneficial for postmenopausal women.